LENZ Therapeutics stock price target raised to $56 from $48 at H.C. Wainwright

LENZ Therapeutics secured FDA approval for VIZZ, its novel aceclidine-based eye drop for presbyopia, positioning it as the first and only eye drop treatment for blurry near vision in adults. This significant development led H.C. Wainwright to raise its price target on LENZ to $56 from $48, while reiterating a Buy rating, citing VIZZ's superior efficacy and safety profile compared to first-generation alternatives. With samples anticipated by October 2025 and full commercial availability by year-end, LENZ is financially prepared with $209.6 million in cash to support its commercialization, including a newly established 88-member sales force, underscoring its strategic market entry.

Analysis

LENZ Therapeutics has achieved a significant regulatory and commercial milestone with the FDA approval of VIZZ, its aceclidine-based eye drop for presbyopia. This catalyst prompted H.C. Wainwright to raise its price target to $56 from $48, reiterating a Buy rating and designating the company as a "2H25 Top Pick." The market opportunity for VIZZ is framed by the stated shortcomings of AbbVie's first-generation product, VUITY, which reportedly disappointed with suboptimal efficacy, durability, and a concerning safety profile. VIZZ's novel mechanism, which targets pupil contraction without engaging the ciliary muscle, is positioned as a superior alternative offering all-day durability and a lower risk of headaches or retinal complications. Operationally, LENZ is preparing for a direct-to-professional commercial launch, with samples slated for October 2025 and full availability by year-end, supported by a newly hired and trained 88-member sales force. Financially, the company appears well-capitalized for this launch, ending its recent quarter with a robust $209.6 million in cash, which management expects will fund operations until post-launch cash flow turns positive, despite a reported Q2 loss of $0.53 per share as it ramps up spending.

Key Decisions for Investors

• Given the FDA approval, strong analyst endorsement, and a clear product differentiation against the incumbent, investors with a bullish outlook on the biotech sector could view LENZ favorably, recognizing VIZZ's potential to capture significant market share in the presbyopia treatment space.
• Monitor the company's execution on its commercialization strategy, paying close attention to physician and patient feedback following the sample rollout in October 2025, as successful market penetration is critical to validating the current valuation.
• Investors should scrutinize quarterly cash burn rates against the company's $209.6 million cash position to ensure the runway to profitability remains on track, as significant launch costs could accelerate spending.
• Keep a close watch on the competitive landscape, including any strategic response from AbbVie or the emergence of new competing therapies that could challenge VIZZ's market position post-launch.